Eric Joseph
Stock Analyst at JP Morgan
(1.84)
# 3,298
Out of 5,241 analysts
116
Total ratings
42.17%
Success rate
-0.59%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Upgrades: Overweight | $10 → $11 | $2.89 | +280.62% | 3 | Dec 17, 2025 | |
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $39.48 | +24.11% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $26.81 | +71.58% | 4 | Oct 9, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $70 → $71 | $144.37 | -50.82% | 7 | Sep 25, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $79.67 | -19.67% | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $3.07 | +128.01% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $2.81 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $8.93 | -21.61% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $70.15 | -4.49% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.13 | - | 4 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.18 | - | 4 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $30 | $15.51 | +93.42% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $8.77 | +59.64% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $26.30 | +44.49% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $4.56 | +404.39% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $6.40 | +165.63% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $12.10 | +73.55% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $13.45 | -25.65% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.25 | +1,100.00% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $3.22 | +86.34% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $18.01 | -38.92% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $16.51 | +505.69% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $2.30 | +117.86% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.14 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $27.67 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $7.14 | +1,580.67% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $5.35 | +5,507.48% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.70 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.80 | +400.00% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.01 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.58 | +1,527.91% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $3.50 | +271.43% | 2 | Jan 24, 2019 |
Recursion Pharmaceuticals
Dec 17, 2025
Upgrades: Overweight
Price Target: $10 → $11
Current: $2.89
Upside: +280.62%
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $39.48
Upside: +24.11%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $26.81
Upside: +71.58%
Revolution Medicines
Sep 25, 2025
Maintains: Overweight
Price Target: $70 → $71
Current: $144.37
Upside: -50.82%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $79.67
Upside: -19.67%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $3.07
Upside: +128.01%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.81
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $8.93
Upside: -21.61%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $70.15
Upside: -4.49%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.13
Upside: -
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.18
Upside: -
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $15.51
Upside: +93.42%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $8.77
Upside: +59.64%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $26.30
Upside: +44.49%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $4.56
Upside: +404.39%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $6.40
Upside: +165.63%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $12.10
Upside: +73.55%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $13.45
Upside: -25.65%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.25
Upside: +1,100.00%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $3.22
Upside: +86.34%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $18.01
Upside: -38.92%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $16.51
Upside: +505.69%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $2.30
Upside: +117.86%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $4.14
Upside: -
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $27.67
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $7.14
Upside: +1,580.67%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $5.35
Upside: +5,507.48%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $11.70
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.80
Upside: +400.00%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.01
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.58
Upside: +1,527.91%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $3.50
Upside: +271.43%